2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.
Cani L, Scott S, Roberts D, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience. Haematologica 2025 PMID: 40905083, DOI: 10.3324/haematol.2025.288187.Peer-Reviewed Original ResearchIntravenous immunoglobulinAnti-BCMAImmune effector cell-associated neurotoxicity syndromePrevention of cytokine release syndromeBispecific antibodiesSingle-center retrospective studyMonthly intravenous immunoglobulinIntravenous immunoglobulin administrationCytokine release syndromeMedian Follow-UpSingle-center experienceAssociated with infection riskInfection riskPrimary prophylaxisHerpes zosterViral loadRetrospective studyNeurotoxicity syndromeCumulative incidenceFollow-upMultivariate analysisRisk factorsProphylactic measuresPatientsBsAb
2024
Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers
Allada S, Gupta V, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Joseph N. Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers. Blood 2024, 144: 7861. DOI: 10.1182/blood-2024-210996.Peer-Reviewed Original ResearchB-cell maturation antigenRefractory myelomaAnti-BCMABispecific antibodiesInternational Myeloma Working Group Uniform Response CriteriaInstitutional experienceWinship Cancer Institute of Emory UniversityCAR-T cell therapyBispecific T-cell engagerSignificant tumor burdenT-cell engagersDecreased performance statusWinship Cancer InstituteRate of gradeLimited treatment optionsStatistically significant differenceMedian PFSPretreated patientsCAR-TMedian followResponse criteriaTumor burdenPretreated populationDose reductionMaturation antigenReal World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel
Akhtar O, Hashmi H, Oloyede T, Brazauskas R, Bye M, Sidana S, Hansen D, Ahmed N, Ferreri C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Pasquini M, Usmani S, Freeman C. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel. Transplantation And Cellular Therapy 2024, 30: s184-s185. DOI: 10.1016/j.jtct.2023.12.239.Peer-Reviewed Original ResearchCytokine-release syndromeProgression-free survivalTreatment-related mortalityClinically significant infectionsRelapse/refractory multiple myelomaOverall survivalIde-celProlonged cytopeniasMultiple myelomaBaseline characteristicsAnti-BCMA CAR-T cell therapyHematopoietic cell transplant-specific comorbidity indexFrail patientsComorbidity indexHigh-grade adverse eventsCAR-T cell therapyRates of overall responseNon-frail patientsRate of neurotoxicityClinically important subgroupsCharlson Comorbidity IndexAge cut-offAnti-BCMAHCT-CIComplete response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply